Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
Hui Ding1, Xi Yang2, Yanzhang Wei3
1Department of Biological Sciences, Clemson University, 190 Collings Street, Clemson, SC 29634, USA. ding4@clemson.edu.
Abstract:
NKG2D (natural killer group 2, member D) is an important activating receptor in natural killer (NK) cells and some T cells. NKG2D ligands (NKG2DLs) are specifically expressed on most tumor cells. The engagement of these ligands on tumor cells to NKG2D on NK cells will induce cell-mediated cytotoxicity and have target cells destroyed. This gives NKG2D/NKG2DLs great potential in cancer therapeutic application. The creation of NKG2D/NKG2DL-based multi-functional fusion proteins is becoming one of the most promising strategies in immunotherapy for cancer. Antibodies, cytokines, and death receptors have been fused with NKG2D or its ligands to produce many powerful fusion proteins, including NKG2D-based chimeric antigen receptors (CARs). In this article, we review the recent developments of the fusion proteins with NKG2D/NKG2DL ligands in cancer immunotherapy.
Insights
Fusion proteins combining NKG2D (natural killer group 2, member D) and its ligands show promise for cancer immunotherapy by enhancing natural killer cell activity against tumors.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- NKG2D (natural killer group 2, member D) is a key activating receptor on NK cells and T cells.
- NKG2D ligands (NKG2DLs) are frequently expressed on tumor cells, mediating target cell destruction upon engagement.
- The NKG2D/NKG2DL axis presents a significant therapeutic target in cancer treatment.
Purpose of the Study:
- To review recent advancements in the development of NKG2D/NKG2DL-based fusion proteins for cancer immunotherapy.
- To highlight the potential of these fusion proteins in enhancing anti-tumor immune responses.
Main Methods:
- Review of literature on fusion proteins incorporating NKG2D or its ligands.
- Analysis of strategies involving antibodies, cytokines, and death receptors fused to NKG2D/NKG2DL.
- Examination of NKG2D-based chimeric antigen receptors (CARs) as a therapeutic modality.
Main Results:
- NKG2D/NKG2DL-based fusion proteins are emerging as a promising strategy in cancer immunotherapy.
- These fusion proteins can be engineered by combining NKG2D or its ligands with other immune-modulating molecules.
- NKG2D-based CARs represent a significant development in this field.
Conclusions:
- Fusion proteins utilizing the NKG2D/NKG2DL interaction offer a potent approach for cancer immunotherapy.
- Further development of these multi-functional fusion proteins holds significant therapeutic potential against various cancers.
Related Concept Videos
Tagging and Fusion Proteins
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Tumor Immunotherapy
SNAREs and Membrane Fusion
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Protein-protein Interfaces


